Safety and Efficacy of Bivalirudin versus Unfractionated Heparin Monotherapy in Patients with CAD and DM Undergoing PCI: A Retrospective Observational Study.
Jing LiSanbao ChenSicong MaMingque YangZizhao QiKun NaMiaohan QiuYi LiYa-Ling HanPublished in: Cardiovascular therapeutics (2022)
In diabetic patients undergoing PCI, bivalirudin was significantly associated with reduced risks of 30-day NACE and MACCE, mainly driven by the lower rates of bleeding and mortality, compared with heparin monotherapy.
Keyphrases
- percutaneous coronary intervention
- coronary artery disease
- cardiovascular events
- patients undergoing
- st segment elevation myocardial infarction
- combination therapy
- st elevation myocardial infarction
- acute myocardial infarction
- antiplatelet therapy
- venous thromboembolism
- acute coronary syndrome
- atrial fibrillation
- coronary artery bypass grafting
- growth factor
- open label
- type diabetes
- coronary artery bypass
- risk factors
- wound healing
- cardiovascular disease
- adipose tissue
- risk assessment
- climate change
- insulin resistance